Medicamen Organics (NSE:MEDIORG) Retained Earnings: ₹0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDIORG Medicamen Organics Ltd NSE:MEDIORG
22 GF Score
Price ₹26.50
! 11 Warning Signs
View Full Analysis

What is Medicamen Organics Retained Earnings?

Medicamen Organics NSE:MEDIORG +3.31% 22 Retained Earnings is ₹0.00 Mil as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 22/100. The stock has 11 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Medicamen Organics's retained earnings for the quarter that ended in Mar. 2026 was ₹0.00 Mil.

Medicamen Organics's quarterly retained earnings increased from Mar. 2024 (₹45.45 Mil) to Mar. 2025 (₹81.25 Mil) but then declined from Mar. 2025 (₹81.25 Mil) to Mar. 2026 (₹0.00 Mil).

Medicamen Organics's annual retained earnings increased from Mar. 2024 (₹45.45 Mil) to Mar. 2025 (₹81.25 Mil) but then declined from Mar. 2025 (₹81.25 Mil) to Mar. 2026 (₹0.00 Mil).


Medicamen Organics  (NSE:MEDIORG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Medicamen Organics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Medicamen Organics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Organics Retained Earnings Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial 10.96 20.66 45.45 81.25 0.00

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Mar25 Mar26
Retained Earnings Get a 7-Day Free Trial 20.66 28.94 45.45 81.25 0.00
NSE:MEDIORG
22GF Score
Medicamen Organics Ltd NSE:MEDIORG
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicamen Organics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹0.00 Mil mean?
Medicamen Organics (NSE:MEDIORG) has a Retained Earnings of ₹0.00 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Medicamen Organics and its competitors.
Is Medicamen Organics' Retained Earnings too high?
Medicamen Organics' current Retained Earnings is ₹0.00 Mil. Overall, Medicamen Organics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Retained Earnings compare to ZTS?
Medicamen Organics' Retained Earnings of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Medicamen Organics and its competitors. Medicamen Organics's current Retained Earnings is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Retained Earnings of ₹0.00 Mil. The current Retained Earnings is ₹0.00 Mil. Medicamen Organics' overall GF Score™ is 22/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Retained Earnings is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicamen Organics Business Description

Address Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
22GF Score

Get the complete analysis for NSE:MEDIORG

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹26.50
Price